Antibody's outside-in signaling shows a route into cancer cells
A new study shows how an anticancer drug triggers an "outside in" signal that gets it sucked into a cancer cell. The work, published Jan. 29 in Nature Communications, reveals a new signaling mechanism ...
Precise binding free energy calculations unlock new frontiers in drug design
Drug discovery is a costly and time-intensive process, with binding free energy calculations between the potential drug ...
BioSpace1d
Algiax’s Non-Opioid Drug Reduces Neuropathic Pain in Mid-Stage Trial
The Phase IIa results continue a surge of momentum in a treatment space that last week saw the approval of Vertex’s Journavx ...
AbbVie's Skyrizi and Rinvoq Have Revived Growth Beyond Humira, Supporting a Wide Moat
AbbVie's acquisition of Allergan significantly increased the firm's debt level. We expect the firm's net debt position to peak at close to $70 billion in 2020 but given the strong cash flows of AbbVie ...
Business Wire6d
PHAXIAM Provides An Update On The Deployment Of Its Strategy To Maximize The Development Potential Of Phage Therapy
PHAXIAM Therapeutics (Euronext: PHXM - FR0011471135), a biopharmaceutical company (“PHAXIAM” or “the Company”) developing innovative ...
JD Supra6d
Rethinking FDA’s Accelerated Approval Pathway: New Draft Guidances and Implications for Drug Companies
The U.S. Food and Drug Administration (FDA) recently issued two new guidance documents governing details of the Accelerated Approval ...